Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 1/2020

01-02-2020 | Antibiotic | Research Article

Impact of ‘Chief-Pharmacist System’ on drug expenditures and rational drug use

Authors: Zhuo Ma, ZhiXia Zhao, ShuSen Sun, YiFan Li, ZhuoLing An, Yan Yan, LiHong Liu

Published in: International Journal of Clinical Pharmacy | Issue 1/2020

Login to get access

Abstract

Background Over the last few years, pharmacists in China have been searching for effective strategies to expand their roles in pharmaceutical care. In September 2012, the Beijing Chaoyang Hospital was the first in China to establish the Chief-Pharmacist System aimed to let pharmacists be a responsible part of the multi-disciplinary care team. Objective To describe the Chief-Pharmacist System and explore its impact on drug expenditures and rational drug use. Setting A tertiary hospital in Beijing, China. Method Chief-Pharmacist System oriented specific measures were implemented and evaluated. Data on medical services quantity, quality and drug expenses during the periods of pre-implementation (from September 1, 2011 to August 31, 2012) and post implementation (from September 1, 2012 to August 31, 2016) were collected. Main outcome measure Healthcare quality indicators, drug expenditures, selected drug use indicators of outpatient and antibiotic use. Results With the implementation of the Chief-Pharmacist System and the participation of pharmacists in pharmaceutical care, drug expenses were reduced significantly. The total drug expenses, outpatient drug expenses per visit and inpatient drug expenses per admission decreased by an average of US $34.3 million, US $8.9 and US $ 303.9, respectively, compared to the pre-implementation period. Meanwhile, selected drug use indicators in post-implementation period were significantly improved. All results were achieved without sacrificing clinical quality and quantity. Conclusion The study illustrates that the Chief-Pharmacist System achieves substantial reductions in drug expenditures and promotion of rational drug use. It provides a model for other hospitals in China and other low- and middle-income countries.
Literature
1.
go back to reference He Y, Dou G, Huang Q, Zhang X, Ye Y, Qian M, et al. Does the leading pharmaceutical reform in China really solve the issue of overly expensive healthcare services? Evidence from an empirical study. PLoS ONE. 2018;13:e0190320.CrossRef He Y, Dou G, Huang Q, Zhang X, Ye Y, Qian M, et al. Does the leading pharmaceutical reform in China really solve the issue of overly expensive healthcare services? Evidence from an empirical study. PLoS ONE. 2018;13:e0190320.CrossRef
3.
go back to reference Fu H, Li L, Li M, Yang C, Hsiao W. An evaluation of systemic reforms of public hospitals: the Sanming model in China. Health Policy Plan. 2017;32:1135–45.CrossRef Fu H, Li L, Li M, Yang C, Hsiao W. An evaluation of systemic reforms of public hospitals: the Sanming model in China. Health Policy Plan. 2017;32:1135–45.CrossRef
4.
go back to reference Doucette WR, Nevins JC, Gaither C, Kreling DH, Mott DA, Pedersen CA, et al. Organizational factors influencing pharmacy practice change. Res Social Adm Pharm. 2012;8:274–84.CrossRef Doucette WR, Nevins JC, Gaither C, Kreling DH, Mott DA, Pedersen CA, et al. Organizational factors influencing pharmacy practice change. Res Social Adm Pharm. 2012;8:274–84.CrossRef
5.
go back to reference Tian W, Yuan J, Yang D, Zhang L. Descriptive analysis on the impacts of universal zero-markup drug policy on a chinese urban tertiary hospital. PLoS ONE. 2016;11:e0162795.CrossRef Tian W, Yuan J, Yang D, Zhang L. Descriptive analysis on the impacts of universal zero-markup drug policy on a chinese urban tertiary hospital. PLoS ONE. 2016;11:e0162795.CrossRef
6.
go back to reference Khdour MR, Kidney JC, Smyth BM, McElnay JC. Clinical pharmacy-led disease and medicine management programme for patients with COPD. Br J Clin Pharmacol. 2009;68:588–98.CrossRef Khdour MR, Kidney JC, Smyth BM, McElnay JC. Clinical pharmacy-led disease and medicine management programme for patients with COPD. Br J Clin Pharmacol. 2009;68:588–98.CrossRef
7.
go back to reference Bond CA, Raehl CL, Patry R. Evidence-based core clinical pharmacy services in United States hospitals in 2020: services and staffing. Pharmacotherapy. 2004;24:427–40.CrossRef Bond CA, Raehl CL, Patry R. Evidence-based core clinical pharmacy services in United States hospitals in 2020: services and staffing. Pharmacotherapy. 2004;24:427–40.CrossRef
8.
go back to reference Dalton K, Byrne S. Role of the pharmacist in reducing healthcare costs: current insights. Integr Pharm Res Pract. 2017;6:37–46.CrossRef Dalton K, Byrne S. Role of the pharmacist in reducing healthcare costs: current insights. Integr Pharm Res Pract. 2017;6:37–46.CrossRef
9.
go back to reference Siaw MYL, Ko Y, Malone DC, Tsou KYK, Lew YJ, Foo D, et al. Impact of pharmacist-involved collaborative care on the clinical, humanistic and cost outcomes of high-risk patients with type 2 diabetes (IMPACT): a randomized controlled trial. J Clin Pharm Ther. 2017;42:475–82.CrossRef Siaw MYL, Ko Y, Malone DC, Tsou KYK, Lew YJ, Foo D, et al. Impact of pharmacist-involved collaborative care on the clinical, humanistic and cost outcomes of high-risk patients with type 2 diabetes (IMPACT): a randomized controlled trial. J Clin Pharm Ther. 2017;42:475–82.CrossRef
10.
go back to reference Houle SK, Chuck AW, McAlister FA, Tsuyuki RT. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN). Pharmacotherapy. 2012;32:527–37.CrossRef Houle SK, Chuck AW, McAlister FA, Tsuyuki RT. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN). Pharmacotherapy. 2012;32:527–37.CrossRef
11.
go back to reference Zhou Y, Ma LY, Zhao X, Tian SH, Sun LY, Cui YM. Impact of pharmacist intervention on antibiotic use and prophylactic antibiotic use in urology clean operations. J Clin Pharm Ther. 2015;40:404–8.CrossRef Zhou Y, Ma LY, Zhao X, Tian SH, Sun LY, Cui YM. Impact of pharmacist intervention on antibiotic use and prophylactic antibiotic use in urology clean operations. J Clin Pharm Ther. 2015;40:404–8.CrossRef
12.
go back to reference Caffiero N, Delate T, Ehizuelen MD, Vogel K. Effectiveness of a clinical pharmacist medication therapy management program in discontinuation of drugs to avoid in the elderly. J Manag Care Spec Pharm. 2017;23:525–31.PubMed Caffiero N, Delate T, Ehizuelen MD, Vogel K. Effectiveness of a clinical pharmacist medication therapy management program in discontinuation of drugs to avoid in the elderly. J Manag Care Spec Pharm. 2017;23:525–31.PubMed
13.
go back to reference Katoue MG, Ker J. Implementing the medicines reconciliation tool in practice: challenges and opportunities for pharmacists in Kuwait. Health Policy. 2018;122:404–11.CrossRef Katoue MG, Ker J. Implementing the medicines reconciliation tool in practice: challenges and opportunities for pharmacists in Kuwait. Health Policy. 2018;122:404–11.CrossRef
14.
go back to reference Doloresco F, Vermeulen LC. Global survey of hospital pharmacy practice. Am J Health Syst Pharm. 2009;66:S13–9.CrossRef Doloresco F, Vermeulen LC. Global survey of hospital pharmacy practice. Am J Health Syst Pharm. 2009;66:S13–9.CrossRef
15.
go back to reference Anderson S. The state of the world’s pharmacy: a portrait of the pharmacy profession. J Interprof Care. 2002;16:391–404.CrossRef Anderson S. The state of the world’s pharmacy: a portrait of the pharmacy profession. J Interprof Care. 2002;16:391–404.CrossRef
16.
go back to reference Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47(3):533–43.PubMed Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47(3):533–43.PubMed
19.
go back to reference Dong L, Yan H, Wang D. Drug prescribing indicators in village health clinics across 10 provinces of Western China. Fam Pract. 2011;28:63–7.CrossRef Dong L, Yan H, Wang D. Drug prescribing indicators in village health clinics across 10 provinces of Western China. Fam Pract. 2011;28:63–7.CrossRef
20.
go back to reference Li Y, Xu J, Wang F, Wang B, Liu L, Hou W, et al. Overprescribing in China, driven by financial incentives, results in very high use of antibiotics, injections, and corticosteroids. Heaalth Aff (Millwood). 2012;31:1075–82.CrossRef Li Y, Xu J, Wang F, Wang B, Liu L, Hou W, et al. Overprescribing in China, driven by financial incentives, results in very high use of antibiotics, injections, and corticosteroids. Heaalth Aff (Millwood). 2012;31:1075–82.CrossRef
21.
go back to reference Zhang HH, Du Y, Liu W, Song SD, Zhao W, Huang GW, et al. Effectiveness of antibiotic use management in Tianjin (2011–2013): a quasi-experimental study. Med Sci Monit. 2017;23:725–31.CrossRef Zhang HH, Du Y, Liu W, Song SD, Zhao W, Huang GW, et al. Effectiveness of antibiotic use management in Tianjin (2011–2013): a quasi-experimental study. Med Sci Monit. 2017;23:725–31.CrossRef
22.
go back to reference Clinical Pharmacy Branch of Chinese Medical Association. Expert consensus on chief pharmacist system of China (2018). Chin J Hosp Adm. 2018;34:793–6. Clinical Pharmacy Branch of Chinese Medical Association. Expert consensus on chief pharmacist system of China (2018). Chin J Hosp Adm. 2018;34:793–6.
23.
go back to reference Yang Z, Fan D. How to solve the crisis behind Bribegate for Chinese doctors. The Lancet. 2012;379:e13–5.CrossRef Yang Z, Fan D. How to solve the crisis behind Bribegate for Chinese doctors. The Lancet. 2012;379:e13–5.CrossRef
Metadata
Title
Impact of ‘Chief-Pharmacist System’ on drug expenditures and rational drug use
Authors
Zhuo Ma
ZhiXia Zhao
ShuSen Sun
YiFan Li
ZhuoLing An
Yan Yan
LiHong Liu
Publication date
01-02-2020
Publisher
Springer International Publishing
Keyword
Antibiotic
Published in
International Journal of Clinical Pharmacy / Issue 1/2020
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-019-00954-9

Other articles of this Issue 1/2020

International Journal of Clinical Pharmacy 1/2020 Go to the issue